COMPANY
EOM Pharmaceuticals
Timeline
- Trial start Phase 1: A Proof-of-Concept Study Evaluating EOM613 in COVID-19 Infected Patients With Severe Symptoms source ↗
Clinical trials (lead sponsor) 1
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT05212532 | A Proof-of-Concept Study Evaluating EOM613 in COVID-19 Infected Patients With Severe Symptoms | Phase 1 | Unknown status (ClinicalTrials.gov) | Aug 9, 2021 | Feb 28, 2022 (estimated) |